DDrare: Database of Drug Development for Rare Diseases

2. 筋萎縮性側索硬化症
［臨床試験数：508，薬物数：530（DrugBank：146），標的遺伝子数：170，標的パスウェイ数：221］

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (2R)-2-Propyloctanoic acid; (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate; (R)-(-)-2-Propyloctaroic acid; 1.0 MIU IL-2 per day; 2.0 MIU IL-2 per day; 250 mg CK-2017357; 4 cholesten-3-one, oxime; 4-cholesten-3-one, oxime; 40 mg GA; 40 mg glatiramer acetate; 5% glucose water solution; 500 mg CK-2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one; AB1010; ALPHA-LIPOIC ACID; ALXN1210; ALZT-OP1a (cromolyn); AMSC; AMX0035; ANX005; AP; AP-101; APO-P001; ARIMOCLOMOL; AT-1501; AVP-923; AZILECT® 1 mg Tabletten; Acetate; Acetylcarnitine; Acthar; Actos 15 mg; Actos 30 mg; Actos 45 mg; Albumin; Albutein 5%; Albúmina humana; Amivita; Anakinra; Arimoclomol; Arundic Acid; Arundic acid; AstroRx; Atropine; Autologous Adipose-derived Mesenchymal Stromal Cells; Autologous MSC-NTF cells; Autologous Mesenchymal stem cells (MSCs); Autologous T-regulatory lymphocytes; Autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded; Autologous adult bone marrow mononuclear cells unexpanded; Autologous bone marrow mononucleated cells; Autologous bone marrow-derived stem cells; Autologous mesenchymal stem cells; Azilect; BHV-0223; BIIB050 / KNS-760704; BIIB050/KNS-760704; BIIB067; BIIB067 (ISIS666853); BIIB078; BIIB100; BIIB105; BIOTIN; BLZ945; BOTOX 100 UNITES ALLERGAN (PR1); BOTULINUM TOXIN TYPE A; BRX-345; Baclofen; Basiliximab; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Betamethasone; Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days; Biologic: IC14 (monoclonal antibody against human CD14); Biotin; Blood sample and environmental survey; Bosutinib; Botox; Botox injection; Botulinum Toxin Type B; Botulinum toxin type A; Botulinum toxin type B (Myobloc); Butylphthalide; CARBOLITHIUM; CARBOLITHIUM*100CPS 150MG; CBD; CC100; CK-2017357; CK-2017357 (Part A); CK-2017357 (Part B); CK-2127107; CK2017357; CNM-Au8; COLCHICINA; COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE; Caffeine; Calogen; Cannabis; Cannabis Sativa extract Oromucosal spray; Cannabis, Medical; Capsaicin; Capsaicin Challenge; Carbidopa; Carbidopa-levodopa; Carbonate; Carbonate de lithium; Ceftriaxone; Celecoxib; Cell-based therapeutics; Cell-based therapy; Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients; Cimetidine; Cimetidine plus Dexpramipexole; Ciprofloxacin; Cistanche Total Glycosides; Clenbuterol; Coenzyme Q10; Colchicina; Colchicine; Colchicine 1 MG Oral Tablet; Combination Product: Active treatment with dual therapy; Control group; Copegus; Copper; Cord blood therapy; Corticotropin; Creatine; Creatine Monohydrate; Creatine monohydrate; Creatinine; Cromolyn; Cu(II)ATSM; Curcumin; Células Mesenquimales de tejido adiposo; Células madre mesenquimales de tejido adiposo autólogo; Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea; DEXMEDETOMIDINE; DEXTRAN SULFATE SODIUM; DNL747; DPA; DaTSCAN; DaTscan; Daraprim; Darunavir; Datscan; Deferiprone; Device: Electrical Impedance Myography; Device: Iowa Oral Performance Instrument; Device: Iowa Oral Pressure Instrument; Device: Micro Mouth Pressure Meter; Device: PowerLung trainer; Device: Pulmonary Function Testing; Device: Stereotactic surgical device; Device: Voluntary Peak Cough Flow Testing; Dexdor; Dexmedetomidine; Dexpramipexole; Dexpramipexole (dose 1); Dexpramipexole (dose 2); Dexpramipexole Dichydrochloride; Dexpramipexole Dihydrochloride; Dextran; Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS); Dextromethorphan; Dextromethorphan HBr and quinidine sulfate; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dolutegravir; Dronabinol; Drug: F 18 T807; Dutasteride; Dutasteride 0.5 mg; E0302 (mecobalamin); EBIXA; EDARAVONE; EH301 (Nicotinamide Riboside/Pterostilbene); EPERISONE; EPI-589; EPREX IV SC 1FL 1ML 40000 UI; EPREX*1SIR 40000UI/ML 1ML; ERYTHROPOIETIN; ESKETAMINE; Edaravone; Endocannabinoid palmitoylethanolamide (PEA); Engensis; Eperisone; Eril®; Erythropoetin (EPO); Erythropoietin; Escitalopram; Esketamine; Ezogabine; FASUDIL HYDROCHLORIDE; FLX-787-ODT; FLX-787-ODT (orally disintigrating tablet); Fasudil; Febuxostat; Fecal microbiota transplantation; Fig; Filgrastim; Fixed dose combination Ciprofloxacin/Celecoxib; Fycompa; G-CSF; GDC-0134; GM604; GSK1223249; GUANA2015; GUANABENZ; GUANABENZ ACETATO; Gilenya; Glatiramer; Glucose; Gold; Gold Nanocrystals; Granulocyte - colony stimulating factor (G-CSF); Granulocyte Colony Stimulating Factor; Growth Hormone (Somatropin); Growth hormone; Guanabenz; HB-adMSCs; HK-001; HUMAN ALBUMIN SOLUTION; HYNR-CS inj; HYNRCS-Allo inj; High-caloric fatty diet; Human Neural Stem Cells; Human albumin; Human autologous mesenchymal stem cells; Hyperpolarized [1-13C]pyruvate; I-123; IBUDILAST; IC14; IL-2; ILB; ILB: 100mg/ml solution for injection and infusion; INTERLEUKIN-2; IPL344; ISIS 333611; Ibudilast; Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy; Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer; Incobotulinum Toxin A; Inosine; Insulin like growth factor, type 1; Interleukin-2; Intra venous injection of stem cell; Intrathecal autologous stem cell; Intrathecal injection; Intravenous administration of 1 million of MSC; Intravenous administration of 2 million of MSC; Intravenous administration of 4 million of MSC; Intraventricular injection; Ioflupane 123I; Isocaloric Diet; Jevity 1.0; Jevity 1.5; KNS-760704; Ketanest; Ketanest-S; KetoCal; L-Serine; LEVOSIMENDAN; LIORESAL*50CPR 10MG; LITHIUM CARBONATE; LITHIUM CITRATE; LITIO CARBONATO; Lacosamide; Lactose; Lenograstim; Leuprolide; Levetiracetam; Levodopa; Levosimendan; Lipoic acid; Lipoic acid group; Liposomed polyphenols resveratrol and curcumin; Lithium; Lithium Apogepha; Lithium Carbonate; Lithium Citrate; Lithium carbonate; Lithium citrate; Lithiumcarbonaat; Lithiumcarbonaat 400 PCH tabletten; Lunasin; Lunasin Regimen; MANNITOLO 18%; MANNITOLO 18% LDB; MASITINIB; MASITINIB MESYLATE; MCI-186; MCI-186 in open label phase; MD1003; MEMANTINE HYDROCHLORIDE; MN-166; MNC (Mononuclear cells); MONITOR; MSC-NTF cells transplantation (IM); MSC-NTF cells transplantation (IT); MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; MT-1186; MYELOSTIM 34*1FL 263MCG+1SIR; MYONAL*30CPR RIV 100MG; Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib 100 mg Tablets; Masitinib 100mg; Masitinib 200 mg Tablets; Masitinib 200mg; Masitinib Mesylate; Masitinib mesylate; Mecobalamin; MediCabilis CBD Oil; Medicine; Memantine; Memantine (Ebixa); Memantine Hydrochloride Oral Solution; Mesenchymal Stromal Cells; Mesenchymal stem cell; Mesenchymal stem cells; Mesenchymal stem cells isolated from Wharton's jelly; Metformin; Methylcobalamin; Methylprednisolone; Mexiletine; Midazolam; Minocycline; Modal; Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections; Moxifloxacin; Multiple Dose; Mycophenolate; Mycophenolate mofetil; Myonal; NP001; NS; Nicotinamide; Nicotinamide riboside; Nuedexta; NurOwn® (MSC-NTF cells); ODM-109; ODM-109 capsule 1 mg; OLANZAPINE; ONO-2506; ONO-2506PO; Olanzapine; Olesoxime; Oral LEVOSIMENDAN; Oral nutritional supplementation; Other:; Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; Other: Communicative Effectiveness Survey; Other: Control group; Other: Eating Assessment Tool 10; Other: Eating Assessment Tool-10; Other: Functional Oral Intake Scale; Other: Historical control; Other: Other: Symptomatic treatment of ALS; Other: Saline; Other: Swallowing Quality of Life Questionnaire; Other: Swallowing Related Quality of Life Questionnaire; Other: The Center for Neurologic Studies Bulbar Function Scale; Other: The Center for Neurologic Study Bulbar Function Scale; Oxepa; Ozanezumab; PARACETAMOLO; PBMC autotransplantation; PERFALGAN; PLECONARIL; PLENUR; PU-AD; PYRIMETHAMINE; Palmitoylethanolamide; Pegcetacoplan (APL-2); Perampanel; Phenylbutyrate; Phosphate; Pimozide; Pimozide 2 mg per day; Pimozide 2mg/day (current) or 4 mg/day (study initiation); Pimozide 4 mg per day; Pioglitazone; Pioglitazone and Tretinoin; Plasma from healthy young people treatment + Riluzole; Pleconaril; PolyMVA; Pramipexole; Prednisone; Pridopidine; Probiotic; Procedure: Injection of salivary glands; Procedure: Pulmonary Function Testing; Procedure: Umbilical cord blood therapy; Procedure: Videofluoroscopic Swallowing Study; Procedure: Videofluoroscopic Swallowing Study (VFSS); Procedure: Videofluoroscopic swallowing study; Proleukin; Proleukin 18 MUI; Prototype capsule GDC-0134; Pyrimethamine; Q-Cells; Quinidine; R(+) pramipexole dihydrochloride monohydrate; RAPA-501 Autologous T cells; RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE; RASAGILINE MESILATE; RAVULIZUMAB; RETIGABINE; RIBAVIRIN; RILUTEK; RILUTEK 50 mg, film-coated tablets; RILUZOLE; RILUZOLO; RNS60; Rabeprazole; Ranolazine; Ranolazine 1000 MG; Ranolazine 500 MG; Rapamune; Rapamycin; Rasagiline; Rasagiline Mesilate; Ravulizumab; ReQuip CR; Recombinant human erythropoietin(rhEPO); Reference capsule GDC-0134; Reldesemtiv; Repository corticotropin injection; Requip CR tablets; Resveratrol; Retigabine; Ribavirin; Rilutek; Rilutek 50 mg film-coated tablets; Riluzole; Riluzole (100 mg); Riluzole 50 MG; Riluzole 50 MG (Part B); Riluzole Oral Soluble Film; Riluzole Oral Soluble film (ROSF) 50 mg; Ritonavir; SB-509; SNN0029; SNN0029 infusion solution; SODIUM PYRUVATE; SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM; SUB126308; Saline solution; Sativex; Scopolamine; Scopolamine, atropine, edaravone and dexmedetomidine; Selective Serotonin Uptake Inhibitors (SSRI); Serine; Serotonin; Single dose reduced; Single dose standard; Sodium Valproate; Sodium phenylbutyrate; Somatropin; Spirit1; Stem Cell; Stem Cells; Stem cell; Stem cell (HPC) implantation; Sulfate; Suspension of human autologous MSC 3P in 1,5 ml; Suspension of human autologous MSC 3P in 1.5 ml; TAUROURSODEOXYCHOLIC ACID; TCH346; TEVAGRASTIM; TRO19622; TUDCA; TUDCABIL; TV-7110; Tacrolimus; Talampanel; Tallampanel; Tamoxifen; Tamoxifen 40 mg daily for one year; Taurolite; Tauroursodeoxycholic Acid; Tauroursodeoxycholic acid; Tauroursodeoxycholic acid (TUDCA); Tenofovir; Tenofovir alafenamide; Tenofovir alafenamide (TAF); Testosterone; Thalidomide; Thalidomide (drug); Theracurmin HP; Tioctic acid; Tirasemtiv; Tocilizumab; Tocotrienols; Trametinib; Trametinib (0.5 mg); Trametinib (1 mg); Trametinib (2 mg); Trazodone; Trazodone Hydrochloride oral solution; Tretinoin; Tretinoin and Pioglitazone HCL; Tricyclic Antidepressants (TCA); Triheptanoin; Triumeq; Trobalt; Téralithe LP; Ultomiris; Ultra-high-caloric carbohydrate-rich diet; Ultra-high-caloric fatty diet; VM202; Valproate; Verdiperstat; Vitamin E; Water; YAM80; ZIBREN*20BUST 500MG; Zibren; Zilucoplan; Zinc; Zinc and Copper; Zyprexa; [11C]MPC6827; [18F] GE-180; [18F]DPA-714 PET; [18F]PBR06; [I-123] ADAM

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-002629-13-BE (EUCTR)	04/09/2017	21/04/2017	An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)	A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 19.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350	Phase 3	Portugal;France;United States;Canada;Spain;Belgium;Ireland;Netherlands;Germany;Italy;United Kingdom
2	EUCTR2016-002629-13-NL (EUCTR)	07/06/2017	14/03/2017	An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)	A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 19.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350	Phase 3	Portugal;France;United States;Canada;Belgium;Spain;Ireland;Germany;Netherlands;Italy;United Kingdom
3	EUCTR2016-002629-13-ES (EUCTR)	12/04/2017	10/03/2017	An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)	A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 19.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350	Phase 3	Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;Italy;United Kingdom
4	EUCTR2016-002629-13-IE (EUCTR)	28/02/2017	25/11/2016	An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)	A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350	Phase 3	Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;Italy;United Kingdom
5	EUCTR2014-005413-23-IE (EUCTR)	30/11/2016	10/09/2015	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)	A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;Italy;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2014-005413-23-IT (EUCTR)	30/05/2016	16/02/2018	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)	A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) - -	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	CYTOKINETICS, INC.	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;United Kingdom;Italy
7	EUCTR2014-005413-23-BE (EUCTR)	20/04/2016	26/02/2016	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)	A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Portugal;France;United States;Canada;Spain;Belgium;Ireland;Netherlands;Germany;Italy;United Kingdom
8	EUCTR2014-005413-23-NL (EUCTR)	06/04/2016	30/11/2015	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)	A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Portugal;France;United States;Canada;Belgium;Spain;Ireland;Germany;Netherlands;Italy;United Kingdom
9	EUCTR2014-005413-23-ES (EUCTR)	09/02/2016	10/12/2015	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)	A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 18.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tirasemtiv Product Code: CK-2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one	Cytokinetics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	445	Phase 3	Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;United Kingdom
10	EUCTR2012-004987-23-ES (EUCTR)	12/06/2013	16/05/2013	A study in which patients suffering from amyotrophic lateral sclerosis (ALS) may be assigned randomly to receive either the treatment or placebo to look at how safe the product is, whether it has an effect and is easy to take.	A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)	Amyotrophic lateral sclerosis MedDRA version: 16.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Tirasemtiv Product Code: CK2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one Trade Name: Rilutek Product Name: Riluzole INN or Proposed INN: RILUZOLE	Cytokinetics Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400	Phase 2b	France;United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	EUCTR2012-004987-23-DE (EUCTR)	29/04/2013	17/01/2013	A study in which patients suffering from amyotrophic lateral sclerosis (ALS) may be assigned randomly to receive either the treatment or placebo to look at how safe the product is, whether it has an effect and is easy to take.	A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)	Amyotrophic lateral sclerosis MedDRA version: 16.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Tirasemtiv Product Code: CK2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one Trade Name: Rilutek Product Name: Riluzole INN or Proposed INN: RILUZOLE	Cytokinetics Inc	NULL	Not Recruiting			Female: yes Male: yes	700	Phase 2b	United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom
12	EUCTR2012-004987-23-IE (EUCTR)	08/02/2013	30/11/2012	A study in which patients suffering from amyotrophic lateral sclerosis (ALS) may be assigned randomly to receive either the treatment or placebo to look at how safe the product is, whether it has an effect and is easy to take.	A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)	Amyotrophic lateral sclerosis MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Tirasemtiv Product Code: CK2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one Trade Name: Rilutek Product Name: Riluzole INN or Proposed INN: RILUZOLE	Cytokinetics Inc	NULL	Not Recruiting			Female: yes Male: yes	700	Phase 2b	United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom
13	EUCTR2012-004987-23-GB (EUCTR)	24/01/2013	12/12/2012	A study in which patients suffering from amyotrophic lateral sclerosis (ALS) may be assigned randomly to receive either the treatment or placebo to look at how safe the product is, whether it has an effect and is easy to take.	A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)	Amyotrophic lateral sclerosis MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]		Cytokinetics Inc	NULL	Not Recruiting			Female: yes Male: yes	700	Phase 2	United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom
14	NCT01709149 (ClinicalTrials.gov)	October 2012	16/10/2012	Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)	A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)	Amyotrophic Lateral Sclerosis	Drug: CK-2017357;Other: Placebo tablets;Drug: Riluzole	Cytokinetics	NULL	Completed	18 Years	N/A	All	711	Phase 2	United States;Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom
15	NCT01486849 (ClinicalTrials.gov)	November 2011	23/11/2011	Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: CK-2017357;Drug: Placebo;Drug: Riluzole 50 MG	Cytokinetics	NULL	Completed	18 Years	N/A	All	27	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT01378676 (ClinicalTrials.gov)	June 2011	20/6/2011	A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Placebo (Part A);Drug: CK-2017357 (Part A);Drug: Riluzole 50 MG (Part B);Drug: Placebo (Part B);Drug: CK-2017357 (Part B)	Cytokinetics	NULL	Completed	18 Years	N/A	All	49	Phase 2	United States
17	NCT01089010 (ClinicalTrials.gov)	March 2010	16/3/2010	A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Placebo;Drug: 250 mg CK-2017357;Drug: 500 mg CK-2017357	Cytokinetics	NULL	Completed	18 Years	N/A	All	67	Phase 2	United States
18	EUCTR2012-004987-23-NL (EUCTR)		07/02/2013	A study in which patients suffering from amyotrophic lateral sclerosis (ALS) may be assigned randomly to receive either the treatment or placebo to look at how safe the product is, whether it has an effect and is easy to take.	A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)	Amyotrophic lateral sclerosis MedDRA version: 16.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Tirasemtiv Product Code: CK2017357 INN or Proposed INN: Tirasemtiv Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one Trade Name: Rilutek Product Name: Riluzole INN or Proposed INN: RILUZOLE	Cytokinetics Inc	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 2b	France;United States;Canada;Spain;Ireland;Germany;Netherlands;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-002629-13-BE
(EUCTR)

04/09/2017

21/04/2017

An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)

A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS

Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 19.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Phase 3

Portugal;France;United States;Canada;Spain;Belgium;Ireland;Netherlands;Germany;Italy;United Kingdom

EUCTR2016-002629-13-NL
(EUCTR)

07/06/2017

14/03/2017

An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)

A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Phase 3

Portugal;France;United States;Canada;Belgium;Spain;Ireland;Germany;Netherlands;Italy;United Kingdom

EUCTR2016-002629-13-ES
(EUCTR)

12/04/2017

10/03/2017

An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)

A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Phase 3

Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;Italy;United Kingdom

EUCTR2016-002629-13-IE
(EUCTR)

28/02/2017

25/11/2016

An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031)

A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031) - VIGOR-ALS

Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

350

Phase 3

Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;Italy;United Kingdom

EUCTR2014-005413-23-IE
(EUCTR)

30/11/2016

10/09/2015

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-005413-23-IT
(EUCTR)

30/05/2016

16/02/2018

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

CYTOKINETICS, INC.

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;United Kingdom;Italy

EUCTR2014-005413-23-BE
(EUCTR)

20/04/2016

26/02/2016

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Portugal;France;United States;Canada;Spain;Belgium;Ireland;Netherlands;Germany;Italy;United Kingdom

EUCTR2014-005413-23-NL
(EUCTR)

06/04/2016

30/11/2015

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

600

Phase 3

Portugal;France;United States;Canada;Belgium;Spain;Ireland;Germany;Netherlands;Italy;United Kingdom

EUCTR2014-005413-23-ES
(EUCTR)

09/02/2016

10/12/2015

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 18.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Tirasemtiv
Product Code: CK-2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one

Cytokinetics, Inc.

NULL

Not Recruiting

Female: yes
Male: yes

445

Phase 3

Portugal;France;United States;Canada;Belgium;Spain;Ireland;Netherlands;Germany;United Kingdom

EUCTR2012-004987-23-ES
(EUCTR)

12/06/2013

16/05/2013

A study in which patients suffering from amyotrophic lateral sclerosis (ALS) may be assigned randomly to receive either the treatment or placebo to look at how safe the product is, whether it has an effect and is easy to take.

A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis
MedDRA version: 16.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]

Product Name: Tirasemtiv
Product Code: CK2017357
INN or Proposed INN: Tirasemtiv
Other descriptive name: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
Trade Name: Rilutek
Product Name: Riluzole
INN or Proposed INN: RILUZOLE

Cytokinetics Inc

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

400

Phase 2b

France;United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2012-004987-23-DE
(EUCTR)

29/04/2013

17/01/2013

A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)

Cytokinetics Inc

NULL

Not Recruiting

Female: yes
Male: yes

700

Phase 2b

United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom

EUCTR2012-004987-23-IE
(EUCTR)

08/02/2013

30/11/2012

A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]

Cytokinetics Inc

NULL

Not Recruiting

Female: yes
Male: yes

700

Phase 2b

United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom

EUCTR2012-004987-23-GB
(EUCTR)

24/01/2013

12/12/2012

A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]

Cytokinetics Inc

NULL

Not Recruiting

Female: yes
Male: yes

700

Phase 2

United States;Canada;Spain;Ireland;Netherlands;Germany;United Kingdom

NCT01709149
(ClinicalTrials.gov)

October 2012

16/10/2012

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)

Amyotrophic Lateral Sclerosis

Drug: CK-2017357;Other: Placebo tablets;Drug: Riluzole

Cytokinetics

NULL

Completed

18 Years

N/A

All

711

Phase 2

United States;Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom

NCT01486849
(ClinicalTrials.gov)

November 2011

23/11/2011

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Drug: CK-2017357;Drug: Placebo;Drug: Riluzole 50 MG

Cytokinetics

NULL

Completed

18 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01378676
(ClinicalTrials.gov)

June 2011

20/6/2011

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Drug: Placebo (Part A);Drug: CK-2017357 (Part A);Drug: Riluzole 50 MG (Part B);Drug: Placebo (Part B);Drug: CK-2017357 (Part B)

Cytokinetics

NULL

Completed

18 Years

N/A

All

Phase 2

United States

NCT01089010
(ClinicalTrials.gov)

March 2010

16/3/2010

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Drug: Placebo;Drug: 250 mg CK-2017357;Drug: 500 mg CK-2017357

Cytokinetics

NULL

Completed

18 Years

N/A

All

Phase 2

United States

EUCTR2012-004987-23-NL
(EUCTR)

07/02/2013

A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)

Cytokinetics Inc

NULL

Not Recruiting

Female: yes
Male: yes

680

Phase 2b

France;United States;Canada;Spain;Ireland;Germany;Netherlands;United Kingdom